Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma

Dr Wenxin Xu - Dana-Farber Cancer Institute, Boston, USA
KIM-1 is a good prognostic and predictive biomarker in advanced renal cell carcinoma ( Dr Wenxin Xu - Dana-Farber Cancer Institute, Boston, USA )
24 Feb 2025

Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer

Dr Anna Dorothea Wagner - Lausanne University Hospital, Lausanne, Switzerland
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer ( Dr Anna Dorothea Wagner - Lausanne University Hospital, Lausanne, Switzerland )
21 Feb 2025

UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC

Dr Sandip Prasad - Garden State Urology, Morristown, USA
UGN-102 shows better results after 12 months of treatment for low-grade intermediate-risk NMIBC ( Dr Sandip Prasad - Garden State Urology, Morristown, USA )
20 Feb 2025

177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC

Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA
177Lu-PSMA-617 with concomitant ARPIs shows is more efficacious than SoC in mCRPC ( Dr Omid Yazdanpanah - University of California Irvine, Irvine, USA )
20 Feb 2025

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC

Prof Camillo Porta - University of Bari, Bari, Italy,
CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC ( Prof Camillo Porta -  University of Bari, Bari, Italy, )
20 Feb 2025

HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone

Dr Nima Sharifi - University of Miami Miller School of Medicine, Miami, USA
HSD3B1 inheritance reduces OS in high-risk nmPC patients on ADT enzalutamide, abiraterone acetate plus prednisolone ( Dr Nima Sharifi -  University of Miami Miller School of Medicine, Miami, USA )
20 Feb 2025

Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC

Prof Thomas Powles - Barts Cancer Institute, London, England
Enfortumab vedotin in combination with pembrolizumab shows improved survival rates in la/mUC ( Prof Thomas Powles - Barts Cancer Institute, London, England )
19 Feb 2025

Ageing and cancer: Inflammation promotes ageing-associated oncogenesis in the lung

Dr James DeGregori - University of Colorado School of Medicine, Aurora, Colorado
Ageing and cancer: Inflammation promotes ageing-associated oncogenesis in the lung ( Dr James DeGregori - University of Colorado School of Medicine, Aurora, Colorado )
17 Feb 2025

Low-dose aspirin can reduce recurrence rates in colorectal cancer patients with PI3K pathway alterations

Prof Anna Martling - Karolinska Institutet, Stockholm, Sweden
Low-dose aspirin can reduce recurrence rates in colorectal cancer patients with PI3K pathway alterations ( Prof Anna Martling - Karolinska Institutet, Stockholm, Sweden )
14 Feb 2025

Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy

Dr Thierry Andre - Sorbonne Université and Saint Antoine Hospital, Paris, France
Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy ( Dr Thierry Andre - Sorbonne Université and Saint Antoine Hospital, Paris, France )
13 Feb 2025

Assessment and management of toxic effects of cancer therapy in elderly patients in Tunisia

Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia
Assessment and management of toxic effects of cancer therapy in elderly patients in Tunisia ( Dr Houda Belfekih - Mohamed Taher Maamouri Hospital, Nabeul, Tunisia )
13 Feb 2025

The use of IORT at Merit Health Surgical Oncology

Dr Phillip Ley - Merit Health Surgical Oncology, Flowood, USA
The use of IORT at Merit Health Surgical Oncology ( Dr Phillip Ley - Merit Health Surgical Oncology, Flowood, USA )
6 Feb 2025